Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND: Siponimod in Secondary Progressive Multiple Sclerosis
NCT01665144Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 31
01
Overview
A Phase 3 trial of siponimod in secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Started Dec 2012; status: completed.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01665144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01665144.